A new bliss independence model to analyze drug combination data

Journal of Biomolecular Screening

Volumn 19, Issue 5, 2014, Pages 817-821

  Zhao, Wei ^a   Sachsenmeier, Kris ^a   Zhang, Lanju ^b   Sult, Erin ^a   Hollingsworth, Robert E ^a   Yang, Harry ^a  

^a MEDIMMUNE   (United States)

^b ABBVIE INC   (United States)

Author keywords

Bliss independence; Drug combination; Drug screening

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; DRUG COMBINATION;

ARTICLE; BLISS INDEPENDENCE MODEL; DATA ANALYSIS; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; DRUG POTENTIATION; DRUG SCREENING; FALSE POSITIVE RESULT; LINEAR REGRESSION ANALYSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RANDOM ERROR; RESPONSE SURFACE METHOD; STATISTICAL MODEL; TOXICITY; ALGORITHM; CHEMICAL MODEL; CHEMISTRY; DRUG RESISTANCE; HUMAN; LUNG TUMOR; METABOLISM; NEOPLASMS; NON SMALL CELL LUNG CANCER; PHARMACEUTICS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MODELS, CHEMICAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 84902211438     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114521867     Document Type: Article

References (14)

1. Natarajan, M.; Lin, K. M.; Hsueh, R. C.; et al. A Global Analysis of Cross-Talk in a Mammalian Cellular Signalling Network. Nat. Cell Biol. 2006, 8, 571-580
2. Ramaswamy, S. Rational Design of Cancer-Drug Combinations. N. Engl. J. Med. 2007, 357, 299-300 (Pubitemid 47080397)
3. Sun, T.; Aceto, N.; Meerbrey, K. L.; et al. Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase. Cell 2011, 144, 703-718
4. Greco, W. R.; Bravo, G.; Parsons, J. C. The Search for Synergy: A Critical Review from a Response Surface Perspective. Pharmacol. Rev. 1995, 47, 331-385
5. Fisz, M. Probability Theory and Mathematical Statistics; John Wiley: New York, 1963
6. Zhao, W.; Zhang, L. J.; Zeng, L. M.; et al. A Two-Stage Response Surface Approach to Modeling Drug Interaction. Stat. Biopharm. Res. 2012, 4, 375-383
7. Novick, S. J. A Simple Test for Synergy for a Small Number of Combinations. Stat. Med. 2013, 32, 5145-5155
8. Belani, C. P.; Goss, G.; Blumenschein, G., Jr. Recent Clinical Developments and Rationale for Combining Targeted Agents in Non-Small Cell Lung Cancer (NSCLC). Cancer Treat. Rev. 2012, 38, 173-184
9. Takahari, D.; Yamada, Y.; Okita, N. T.; et al. Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer. Oncology 2009, 76, 42-48
10. Riedemann, J.; Takiguchi, M.; Sohail, M.; et al. The EGF Receptor Interacts with the Type 1 IGF Receptor and Regulates Its Stability. Biochem. Biophys. Res. Commun. 2007, 355, 707-714
11. Jameson, M. J.; Beckler, A. D.; Taniguchi, L. E.; et al. Activation of the Insulin-Like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells. Mol. Cancer Ther. 2011, 10, 2124-2134
12. Dong, J.; Sereno, A.; Aivazian, D.; et al. A Stable IgG-Like Bispecific Antibody Targeting the Epidermal Growth Factor Receptor and the Type I Insulin-Like Growth Factor Receptor Demonstrates Superior Anti-Tumor Activity. mAbs 2011, 3, 273-288
13. Galer, C. E.; Corey, C. L.; Wang, Z.; et al. Dual Inhibition of Epidermal Growth Factor Receptor and Insulin-Like Growth Factor Receptor I: Reduction of Angiogenesis and Tumor Growth in Cutaneous Squamous Cell Carcinoma. Head Neck 2011, 33, 189-198
14. Sachsenmeier, K. F.; Dimasi, N.; Huang, Q. H.; et al. The Avidity Hypothesis: Comparing Bi-specific and Monospecific Antibodies in Pre-clinical Oncology Models. Platform Presentation. American Association for Cancer Research Annual Meeting; Washington, DC, April 9, 2013.